ITOS ITeos Therapeutics
- 10.800
- +0.200+1.89%
- 10.800
- 0.0000.00%
ITeos Therapeutics News
Analysts Offer Insights on Healthcare Companies: ITeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
ITeos Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and ITeos Therapeutics (ITOS)
Analysts Are Bullish on These Healthcare Stocks: ITeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
ITeos Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $44 Price Target
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), ITeos Therapeutics (ITOS) and Rezolute (RZLT)
Wedbush Adjusts ITeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating
ITeos Therapeutics' Anticipated Growth and Clinical Updates Drive Buy Rating: An Analyst's Perspective
ITeos Therapeutics Analyst Ratings
Positive Financial Results and Promising Cancer Treatment Programs Underpin Buy Rating for ITeos Therapeutics
ITeos Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Lowers Price Target to $44
ITeos Therapeutics Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on ITeos Therapeutics (ITOS)
SVB Securities Remains a Buy on ITeos Therapeutics (ITOS)
ITeos Therapeutics (ITOS) Gets a Buy From H.C. Wainwright
H.C. Wainwright Sticks to Its Buy Rating for ITeos Therapeutics (ITOS)
JPMorgan Chase Adjusts Price Target on ITeos Therapeutics to $32 From $34, Maintains Overweight Rating
Wedbush Lowers ITeos Therapeutics' Price Target to $33 From $45 Following Model Update; Keeps Outperform Rating
Analysis
Price Target
No Data
